Medivation Inc.

New name, plans to domicile in Switzerland reflect maturation of oncology player 

Plus: BeiGene adds to commercial leadership, hiring Pfizer veteran Matt Shaulis, and updates from Wells Fargo, Flagship, Alume, Cytek, Aetion and 180 Life Sciences

Plus: Medivation vet Hung now chair of T-Therapeutics and updates from Voyager and Eyenuk

Plus Concert preps JAK1/2 NDA and updates from Otonomy, Stealth and more

Plus Sutro gains $90M up front in Astellas ADC deal and updates for Nuvation, Astellas, Stealth, Reistone and Axsome

How the once maligned SPAC has become a viable IPO option for top-tier biotechs

Cancer company gaining $644M through deal with EcoR1’s Panacea, PIPE

Why Omega Funds is keeping a balanced approach with its latest and largest fund

With a management team stocked with ex-Medivation execs, Nuvation aims to develop a broad oncology pipeline